188 related articles for article (PubMed ID: 15988352)
1. [Isotretinoin: compliance with recommendations in childbearing women].
Bensouda-Grimaldi L; Jonville-Béra AP; Mouret E; Elefant E; Dhellot H; Delmas C; Gouin T; Coste P; Autret-Leca E;
Ann Dermatol Venereol; 2005 May; 132(5):415-23. PubMed ID: 15988352
[TBL] [Abstract][Full Text] [Related]
2. [Isotretinoin in childbearing women: compliance with strengthen warnings].
Autret-Leca E; Jonville-Béra AP; Szafir D; Cissoko H; Boulkroun Y; Goehrs JM
Ann Dermatol Venereol; 2000 Oct; 127(10):808-13. PubMed ID: 11060382
[TBL] [Abstract][Full Text] [Related]
3. [Isotretinoin (Roaccutane) in women of childbearing age: failure of following prescription guidelines].
Autret E; Radal M; Jonville-Béra AP; Goehrs JM
Ann Dermatol Venereol; 1997; 124(8):518-22. PubMed ID: 9740842
[TBL] [Abstract][Full Text] [Related]
4. Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France.
Autret-Leca E; Kreft-Jais C; Elefant E; Cissoko H; Darrouzain F; Grimaldi-Bensouda L; Attia S; Jonville-Béra AP
Drug Saf; 2010 Aug; 33(8):659-65. PubMed ID: 20635824
[TBL] [Abstract][Full Text] [Related]
5. Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data.
Teichert M; Visser LE; Dufour M; Rodenburg E; Straus SM; De Smet PA; Stricker BH
Drug Saf; 2010 Apr; 33(4):315-26. PubMed ID: 20297863
[TBL] [Abstract][Full Text] [Related]
6. [Exposure to isotretinoin during pregnancy in France: 25 years of follow-up].
Rouzès A; Jonville-Béra AP
Therapie; 2014; 69(1):53-63. PubMed ID: 24698189
[TBL] [Abstract][Full Text] [Related]
7. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program.
Brinker A; Kornegay C; Nourjah P
Arch Dermatol; 2005 May; 141(5):563-9. PubMed ID: 15897377
[TBL] [Abstract][Full Text] [Related]
8. Dermatologists' level of compliance with the prescription guidelines of isotretinoin for females of childbearing potential.
AlGhamdi KM; Khurram H; Asiri YA; Mandil A
Int J Dermatol; 2011 Sep; 50(9):1094-8. PubMed ID: 22126870
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of compliance with isotretinoin PPP recommendations and exploration of reasons for non-compliance: Survey among French-speaking health care professionals and patients in Belgium.
Lelubre M; Hamdani J; Senterre C; Amighi K; Peres M; Schneider MP; Bugnon O; De Vriese C
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):668-673. PubMed ID: 29726056
[TBL] [Abstract][Full Text] [Related]
10. A pregnancy-prevention program in women of childbearing age receiving isotretinoin.
Mitchell AA; Van Bennekom CM; Louik C
N Engl J Med; 1995 Jul; 333(2):101-6. PubMed ID: 7777014
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy prevention among women taking isotretinoin: failure to comply with the recommendations.
Boucher N; Beaulac-Baillargeon L
Can Fam Physician; 2006 Mar; 52(3):338-9. PubMed ID: 16926960
[TBL] [Abstract][Full Text] [Related]
12. Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review.
Crijns HJ; Straus SM; Gispen-de Wied C; de Jong-van den Berg LT
Br J Dermatol; 2011 Feb; 164(2):238-44. PubMed ID: 20716214
[TBL] [Abstract][Full Text] [Related]
13. Compliance with pregnancy prevention measures during isotretinoin therapy.
Collins MK; Moreau JF; Opel D; Swan J; Prevost N; Hastings M; Bimla Schwarz E; Korb Ferris L
J Am Acad Dermatol; 2014 Jan; 70(1):55-9. PubMed ID: 24157382
[TBL] [Abstract][Full Text] [Related]
14. Accutane-exposed pregnancies--California, 1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2000 Jan; 49(2):28-31. PubMed ID: 10680601
[TBL] [Abstract][Full Text] [Related]
15. Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin.
Raguideau F; Mezzarobba M; Zureik M; Weill A; Ricordeau P; Alla F
Pharmacoepidemiol Drug Saf; 2015 May; 24(5):526-33. PubMed ID: 25753265
[TBL] [Abstract][Full Text] [Related]
16. Use of the Retinoid Pregnancy Prevention Program in Canada: patterns of contraception use in women treated with isotretinoin and etretinate.
Pastuszak A; Koren G; Rieder MJ
Reprod Toxicol; 1994; 8(1):63-8. PubMed ID: 8186626
[TBL] [Abstract][Full Text] [Related]
17. Women's experiences with isotretinoin risk reduction counseling.
Werner CA; Papic MJ; Ferris LK; Lee JK; Borrero S; Prevost N; Schwarz EB
JAMA Dermatol; 2014 Apr; 150(4):366-71. PubMed ID: 24258663
[TBL] [Abstract][Full Text] [Related]
18. Continued occurrence of Accutane-exposed pregnancies.
Honein MA; Paulozzi LJ; Erickson JD
Teratology; 2001 Sep; 64(3):142-7. PubMed ID: 11514944
[TBL] [Abstract][Full Text] [Related]
19. Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance.
MacDonald SC; Cohen JM; Panchaud A; McElrath TF; Huybrechts KF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1211-1221. PubMed ID: 31328328
[TBL] [Abstract][Full Text] [Related]
20. Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies.
Lagan BM; Dolk H; White B; Uges DR; Sinclair M
Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):411-8. PubMed ID: 24493556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
